Andrew Farnum

Andrew Farnum is the CEO of Variant Bio, a company developing therapies by studying the genes of people with exceptional health-related traits. Variant has dozens of genomic research partnerships on six continents, working hand in hand with communities that have not previously participated in genomic research. Before Variant, Andrew was the Director of the Gates Foundation’s Strategic Investment Fund, where he led the foundation’s $2 billion investment program and chaired the foundation’s investment committee. Earlier, Andrew was an investor and investment banker at TPG and Goldman Sachs. Andrew has a master’s degree in international development from the Harvard Kennedy School and an AB in molecular biology from Princeton University.